Cordonnier Michael
Known title: CEO, PresidentCIK: 0002077087
Associated companies
Transaction History
| CARL | ▲ Buy | Option Exercise | 160,567 | $54K | 3/3/2026 | View on chart |
| CARL | ▲ Buy | Option Exercise | 33,264 | $145K | 3/3/2026 | View on chart |
| CARL | ▲ Buy | Option Exercise | 197,855 | $66K | 3/2/2026 | View on chart |
| CARL | ▼ Sell | Open Market | 197,855 | $2.6M | 3/2/2026 | View on chart |
| CARL | ▲ Buy | Grant | 117,316 | $0 | 1/28/2026 | View on chart |
| CARL | ▲ Buy | Option Exercise | 3,612 | — | 7/24/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed
Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.
CARL CFO Appointment and FY2026 Revenue Guidance Confirmed. Carlsmed announced Richard Heppenstall as its new chief financial officer, succeeding Leo Greenstein. The company also reaffirmed its FY2026 sales guidance of $74 million to $78 million, matching analyst estimates. BTIG kept its price target at $23 following the announcements.